Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: services pharmaco risk cfm
… 2017 US birth cohort . Pediatrics. 2022 Jul 13. Related Services Health Economics Staff Members Justin Carrico Sandra …
JCA Development and Support We can be your expert partner for education and guidance throughout the whole development process including JCA impact on your product pipeline. We can help you with: JCA dossier and evidence refinement Post-submission support …
… patients, providers, and third-party payers. Related Services Health Economics …
Tailoring Cost-Effectiveness Modeling Methodologies for Multiple Sclerosis Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple …
A Global Review of Quality-of-Life Impact A Global Review of Quality-of-Life Impact of Atopic Dermatitis in Children Miles L , Purser M Transcript: One in four children in developed countries is diagnosed with atopic dermatitis, or AD, which is …
Trends in the Inclusion of Patient Reported Outcomes in Oncology Clinical Trials Margaret Mordin, MS Vice President, Market Access and Outcomes Strategy RTI Health Solutions Trends in the inclusion of patient reported outcomes in oncology clinical trials: …
… biopharmaceutical companies research and consulting services in health economics, patient-centered outcomes …
How Do We Get Drug Labeling Based on Patient Reported Outcomes? With Ari Gnanasakthy , MBA, MSc, Principal Scientist, Patient-Centered Outcomes Assessment at RTI Health Solutions. Transcript A frequent request we receive from clients relates to labeling, …
ICPE Annual Conference 2023 Share on: Wednesday, August 23 - Sunday, August 27, 2023 Conference website ICPE 2023: The Global Home for the Science of Real-World Evidence We are pleased to be a gold sponsor of ICPE 2023. We will also be attending, …
HTA and Reimbursement Considerations for Orphan Drugs in European Markets HTA and Reimbursement Considerations for Rare Diseases in European Markets: What Are the Implications for Manufacturers? Heyes A, McBride D, Pearson I, Copley-Merriman C …